ReviewCellular and molecular life sciences : CMLS2022
Preclinical models of epithelial ovarian cancer: practical considerations and challenges for a meaningful application.
Review in Cellular and molecular life sciences : CMLS, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 41 citations in OpenAlex.
- Refining OVCAR-3 xenograft models of peritoneal carcinomatosis in nu/nu mice: Comparative intraperitoneal implantation strategies and the role of basement membrane matrix.Animal models and experimental medicine · 2026Article
- Review
- Article
- Investigating PAK inhibition in combination with PD-1 blockade to enhance cytotoxic CD8+ T cell-mediated killing and suppress invasion of ovarian cancer cells.British journal of cancer · 2026Article
- An Advanced 3D Model of Vascularized Epithelial Ovarian Cancer in a Tumor-on-a-Chip System Based on Multi-Cell Culture.Sensors (Basel, Switzerland) · 2026Article
- Advances in Next-Generation Immunotherapies for Ovarian Cancer: Mechanisms of Immune Evasion and Novel Therapeutic Targets.Biomolecules · 2026Review
- High-grade serous ovarian cancer induced in different sites of origin in mice exemplifies diverse features of the human disease.iScience · 2026Article
- Tumour-on-Chip Models for the Study of Ovarian Cancer: Current Challenges and Future Prospects.Cancers · 2025Review
- Organoid models established from primary tumors and patient-derived xenograft tumors reflect platinum sensitivity of ovarian cancer patients.BMC cancer · 2025Article
- Amphiregulin Downregulates E-cadherin Expression by Activating YAP/Egr-1/Slug Signaling in SKOV3 Human Ovarian Cancer Cells.Reproductive sciences (Thousand Oaks, Calif.) · 2025Article
- Regulation of volume-regulated anion channels alters sensitivity to platinum chemotherapy.Science advances · 2024Article
- Exploration of organoids in ovarian cancer: From basic research to clinical translation.Translational oncology · 2024Review
- Comparison of two-dimensional and three-dimensional culture systems and their responses to chemotherapy in cells representing disease progression of high-grade serous ovarian cancer.Biochemistry and biophysics reports · 2024Article
- Ovarian cancer cells exhibit diverse migration strategies on stiff collagenous substrata.Biophysical journal · 2024Article
- Metallo-protease Peptidase M84 fromiScience · 2024Article
- Zebrafish Avatars: Toward Functional Precision Medicine in Low-Grade Serous Ovarian Cancer.Cancers · 2024Article
- What value do zebrafish have to anticancer drug discovery?Expert opinion on drug discovery · 2024Article
- Development of a long term, ex vivo, patient-derived explant model of endometrial cancer.PloS one · 2024Article
- Zebrafish as a model system for studying reproductive diseases.Frontiers in cell and developmental biology · 2024Review
- Targeted radiopharmaceuticals: an underexplored strategy for ovarian cancer.Theranostics · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite many improvements in ovarian cancer diagnosis and treatment, until now, conventional chemotherapy and new biological drugs have not been shown to cure the disease, and the overall prognosis remains poor. Over 90% of ovarian malignancies are categorized as epithelial ovarian cancers (EOC), a collection of different types of neoplasms with distinctive disease biology, response to chemotherapy, and outcome. Advances in our understanding of the histopathology and molecular features of EOC subtypes, as well as the cellular origins of these cancers, have given a boost to the development of clinically relevant experimental models. The overall goal of this review is to provide a comprehensive description of the available preclinical investigational approaches aimed at better characterizing disease development and progression and at identifying new therapeutic strategies. Systems discussed comprise monolayer (2D) and three-dimensional (3D) cultures of established and primary cancer cell lines, organoids and patient-derived explants, animal models, including carcinogen-induced, syngeneic, genetically engineered mouse, xenografts, patient-derived xenografts (PDX), humanized PDX, and the zebrafish and the laying hen models. Recent advances in tumour-on-a-chip platforms are also detailed. The critical analysis of strengths and weaknesses of each experimental model will aid in identifying opportunities to optimize their translational value.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.